

Interview Summary	Application No.		Applicant(s)	
	09/652,292		BOWDEN ET AL.	
	Examiner		Art Unit	
	Prema M Mertz		1646	

All participants (applicant, applicant's representative, PTO personnel):

(1) Prema M Mertz (Primary Examiner).

(3) _____.

(2) Kenneth Sibley (Attorney).

(4) _____.

Date of Interview: 14 July 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference

c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.

If Yes, brief description: _____.

Claim(s) discussed: 1-9 and 36.

Identification of prior art discussed: none.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Prema Mertz

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: It was indicated to Mr. Sibley that amending the pending claims to recite a nucleic acid encoding a protein comprising the amino acid sequence set forth in SEQ ID NO:2 would obviate the 35 USC 112, first para written description and enablement rejections, the 35 USC 112, second para rejection, the 35 USC 102(b) rejection over Marra et al and the 35 USC 101 rejection for the absence of the term "isolated or purified. Other pertinent amendments to the claims were discussed and Attorney would submit a supplemental amendment canceling all the pending claims and adding new claims.